Department of Ophthalmology and Visual Science, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Jpn J Ophthalmol. 2023 Sep;67(5):565-569. doi: 10.1007/s10384-023-01010-w. Epub 2023 Jul 16.
PURPOSE: To evaluate the efficacy of azithromycin hydrate ophthalmic solution for the treatment of internal hordeolum and meibomitis with or without phlyctenular keratitis. STUDY DESIGN: Retrospective study. METHODS: Patients diagnosed with internal hordeolum or meibomitis were prescribed azithromycin hydrate ophthalmic solution twice daily for 2 days and then once daily for 12 days. Depending on the presence of meibomitis-related keratoconjunctivitis (MRKC), we further divided the patients with meibomitis into three subgroups: meibomitis alone (non-MRKC group), meibomitis with non-phlyctenular MRKC (non-phlyctenular group), and meibomitis with phlyctenular MRKC (phlyctenular group). Inflammatory findings (eyelid redness and conjunctival hyperemia) were scored before and after treatment. Some patients also underwent culture testing fluids discharged by the meibomian gland orifices. RESULTS: Three patients (3 eyes) had internal hordeolum and 16 patients (16 eyes) had meibomitis. After treatment, the inflammatory findings disappeared in all eyes with internal hordeolum. Among the patients with meibomitis, three eyes were in the non-MRKC, six in the non-phlyctenular, and seven in the phlyctenular group. The inflammatory findings were significantly improved only in the phlyctenular group. Among seven eyes with positive culture results, Cutibacterium acnes was detected in five, and treatment improved the inflammatory findings in all of these eyes. CONCLUSION: Azithromycin hydrate ophthalmic solution is effective for the treatment of inflammatory meibomian gland diseases, including internal hordeolum and meibomitis. In particular, the agent is highly efficient in patients with phlyctenular MRKC.
目的:评估琥乙红霉素滴眼液治疗伴有或不伴有滤泡性角结膜炎的内麦粒肿和睑板腺炎的疗效。
研究设计:回顾性研究。
方法:诊断为内麦粒肿或睑板腺炎的患者,给予琥乙红霉素滴眼液,每日 2 次,连用 2 天,然后每日 1 次,连用 12 天。根据是否存在与睑板腺相关的角结膜炎(MRKC),我们进一步将患有睑板腺炎的患者分为三组:单纯睑板腺炎(非-MRKC 组)、非滤泡性 MRKC 相关的睑板腺炎(非滤泡性组)和滤泡性 MRKC 相关的睑板腺炎(滤泡性组)。治疗前后对眼睑红肿和结膜充血等炎症表现进行评分。部分患者还对睑板腺开口排出的分泌物进行了培养检测。
结果:3 例(3 只眼)患有内麦粒肿,16 例(16 只眼)患有睑板腺炎。治疗后,所有内麦粒肿患者的炎症表现均消失。在患有睑板腺炎的患者中,非-MRKC 组 3 只眼,非滤泡性组 6 只眼,滤泡性组 7 只眼。仅在滤泡性组中,炎症表现明显改善。在 7 只培养结果阳性的眼中,5 只检测到痤疮丙酸杆菌,所有这些眼的炎症表现均得到改善。
结论:琥乙红霉素滴眼液对治疗包括内麦粒肿和睑板腺炎在内的炎症性睑板腺疾病有效。特别是,该药物在患有滤泡性 MRKC 的患者中具有很高的疗效。
Ocul Surf. 2015-2-18
Diagnostics (Basel). 2024-2-23
Am J Ophthalmol. 2005-7
Invest Ophthalmol Vis Sci. 2018-11-1
Microorganisms. 2024-8-12
Ocul Surf. 2015-2-18
Clin Ophthalmol. 2010-7-30
J Ocul Pharmacol Ther. 2009-10
Ophthalmology. 1982-10